Company / Financials
Lineage Cell Therapeutics, Inc. Financials
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$14.6M
FY2025 · +53.2% YoY
Net Income
-$63.5M
FY2025 · -241.4% YoY
Profit Margin
-436.5%
FY2025 · net income / revenue
ROE
-142.6%
FY2025 · return on equity
Total Assets
$112.6M
FY2025
Total Debt
-
FY2025
Equity
$44.5M
FY2025
ROA
-56.4%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -3.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$14.6M+53.2% YoYNet Income HistoryProfit after all expenses and taxes-$63.5M-241.4% YoYGross Profit HistoryRevenue minus cost of goods sold-Cost of Revenue HistoryDirect costs of producing goods and services sold-Operating Income HistoryProfit from core business operations before interest and taxes-$36.6M-70.5% YoYSG&A Expense HistorySelling, general, and administrative expenses$18.5M+1.6% YoYR&D Expense HistoryResearch and development spending$17.7M+42.2% YoYInterest Expense HistoryCost of borrowing and debt obligations-Income Tax HistoryTotal income tax expense-$5.3MEPS (Basic) HistoryBasic earnings per share-$0.09+25.0% YoY